Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates

Journal of Clinical Microbiology

Volumn 36, Issue 4, 1998, Pages 958-964

  McSharry, James M ^a   Lurain, Nell S ^b   Drusano, George L ^a   Landay, Alan ^b   Manischewitz, Jody ^c   Nokta, Mostafa ^d   O'Gorman, Maurice ^e   Shapiro, Howard M ^f   Weinberg, Adriana ^g   Reichelderfer, Patricia ^h   Crumpacker, Clyde ⁱ  

^a ALBANY MEDICAL COLLEGE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f Medical Center ^*

^g UNIVERSITY OF COLORADO   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROCHROME; GANCICLOVIR;

ARTICLE; CYTOMEGALOVIRUS; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY;

EID: 0031945437     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.36.4.958-964.1998     Document Type: Article

References (22)

1. Crumpacker, C. S. 1996. Drug resistance in cytomegalovirus: current knowledge and implications for patient management. J. Acquired Immune Defic. Syndr. 12(Suppl. 1):S-S18.
2. Crumpacker, C. S. 1996. Ganciclovir. N. Engl. J. Med. 335:721-729.
3. Danker, W. M., S. Scholl, S. C. Stanat, M. Martin, R. L. Sonke, and S. A. Spector. 1990. Rapid antiviral DNA-DNA hybridization assay for human cytomegalovirus. J. Virol. Methods 28:293-298.
4. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resources, Los Angeles, Calif.
5. Dieterich, D. T., M. A. Polis, E. A. Lew, P. E. Mendez, R. Murphy, A. Addessi, J. T. Holbrook, K. Naughton, and D. N. Friedberg. 1993. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J. Infect. Dis. 167:1184-1188.
6. Drew, W. L. 1989. Cytomegalovirus infection in patients with AIDS. J. Infect. Dis. 158:449-456.
7. Drew, W. L. 1992. Nonpulmonary manifestations of cytomegalovirus infection in immunocompromised patients. Clin. Microbiol. Rev. 5:204-210.
8. Drew, W. L., R. C. Miner, D. F. Busch, S. E. Follansbee, J. Gullett, S. G. Mehalko, S. M. Gordon, W. F. Owen, Jr., T. R. Mathews, W. C. Buhles, and B. DeArmond. 1991. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J. Infect. Dis. 163:716-719.
9. Elmendorf, S., J. J. McSharry, J. Laffin, D. Fogleman, and J. M. Lehman. 1988. Detection of an early cytomegalovirus antigen with two color quantitative flow cytometry. Cytometry 9:254-260.
10. Gerna, F., A. Sarasini, E. Percivalle, M. Zavattoni, F. Baldanti, and M. G. Revello. 1995. Rapid screening for resistance to ganciclovir and foscarnet resistance of primary isolates of human cytomegalovirus from cullure-positive blood samples. J. Clin. Microbiol. 33:738-741.
11. Jacobson, M. A., and J. Mills. 1988. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 108:588-594.
12. Jokela, J., A. Erice, S. Stanat, W. L. Drew, S. Spector, A. Weinberg, B. Gilliam, B. Yen-Lieberman, J. Manischewitz, R. Pollard, M. Landry, S. Chou, K. K. Biron, P. Reichelderfer, W. Britt, and C. Crumpacker. 1995. A standardized plaque reduction assay for CMV antiviral susceptibility, abstr. 283. In Abstracts of the 2nd National Conference on Human Retroviruses.
13. Lipson, S. M., M. Soni, F. X. Biondo, D. H. Shepp, M. H. Kaplan, and T. Sun. 1997. Antiviral susceptibility testing-flow cytometric analysis (ASTFCA) for the detection of cytomegalovirus drug resistance. Diagn. Microbiol. Infect. Dis. 28:123-129.
14. Lurain, N. S., K. D. Thompson, E. W. Holmes, and G. S. Read. 1992. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J. Virol. 66:7146-7152.
15. McSharry, J. J. 1994. Uses of flow cytometry in virology. Clin. Microbiol. Rev. 7:576-604.
16. McSharry, J. J. 1995. Flow cytometry-based antiviral resistance assays. Clin. Immunol. Newsl. 15:113-119.
17. Mocarski, E. S., Jr. 1996. Cytomegaloviruses and their replication, p. 2447-2492. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology. Lippincott-Raven Publishers, Philadelphia, Pa.
18. Oberg, B. 1983. Antiviral effects of phosphonoformate. Pharmacol. Ther. 19:387-415.
19. Pavić, I., A. Hartmann, A. Zimmermann, D. Michel, W. Hampl, I. Schleyer, and T. Mertens. 1997. Flow cytometric analysis of herpes simplex virus type 1 susceptibility to acyclovir, ganciclovir, and foscarnet. Antimicrob. Agents Chemother. 41:2686-2692.
20. Polis, M. A., K. M. Spooner, B. F. Baird, J. Manischewitz, H. S. Jaffe, P. E. Fisher, J. Falloon, R. T. Davey, Jr., J. A. Kovacs, R. E. Walker, S. M. Whitcup, R. B. Nussenblatt, H. C. Lane, and H. Masur. 1995. Anticytomegalovirus activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob. Agents Chemother. 39:882-886.
21. Schols, D., R. Snoeck, J. Neyts, and E. DeClercq. 1989. Detection of immediate early, early and late antigens of human cytomegalovirus by flow cytometry. J. Virol. Methods 26:247-254.
22. Wentworth, B. B., and L. French. 1970. Plaque assay of cytomegalovirus strains of human origin. Proc. Soc. Exp. Biol. Med. 135:253-258.